Literature DB >> 20182459

Awakening dormant haematopoietic stem cells.

Andreas Trumpp1, Marieke Essers, Anne Wilson.   

Abstract

Haematopoietic stem cells (HSCs) in mouse bone marrow are located in specialized niches as single cells. During homeostasis, signals from this environment keep some HSCs dormant, which preserves long-term self-renewal potential, while other HSCs actively self renew to maintain haematopoiesis. In response to haematopoietic stress, dormant HSCs become activated and rapidly replenish the haematopoietic system. Interestingly, three factors - granulocyte colony-stimulating factor, interferon-alpha and arsenic trioxide - have been shown to efficiently activate dormant stem cells and thereby could break their resistance to anti-proliferative chemotherapeutics. Thus, we propose that two-step strategies could target resistant leukaemic stem cells by priming tumours with activators of dormancy followed by chemotherapy or targeted therapies.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20182459     DOI: 10.1038/nri2726

Source DB:  PubMed          Journal:  Nat Rev Immunol        ISSN: 1474-1733            Impact factor:   53.106


  80 in total

1.  A pilot study of continuous imatinib vs pulsed imatinib with or without G-CSF in CML patients who have achieved a complete cytogenetic response.

Authors:  M W Drummond; N Heaney; J Kaeda; F E Nicolini; R E Clark; G Wilson; P Shepherd; J Tighe; L McLintock; T Hughes; T L Holyoake
Journal:  Leukemia       Date:  2009-03-05       Impact factor: 11.528

Review 2.  Concise review: stem cell antigen-1: expression, function, and enigma.

Authors:  Christina Holmes; William L Stanford
Journal:  Stem Cells       Date:  2007-03-22       Impact factor: 6.277

3.  Tie2/angiopoietin-1 signaling regulates hematopoietic stem cell quiescence in the bone marrow niche.

Authors:  Fumio Arai; Atsushi Hirao; Masako Ohmura; Hidetaka Sato; Sahoko Matsuoka; Keiyo Takubo; Keisuke Ito; Gou Young Koh; Toshio Suda
Journal:  Cell       Date:  2004-07-23       Impact factor: 41.582

4.  A low level of reactive oxygen species selects for primitive hematopoietic stem cells that may reside in the low-oxygenic niche.

Authors:  Yoon-Young Jang; Saul J Sharkis
Journal:  Blood       Date:  2007-06-26       Impact factor: 22.113

Review 5.  The role of interferon-alpha in the treatment of chronic myeloid leukemia.

Authors:  Lisa A Kujawski; Moshe Talpaz
Journal:  Cytokine Growth Factor Rev       Date:  2007-08-20       Impact factor: 7.638

6.  Purification and characterization of mouse hematopoietic stem cells.

Authors:  G J Spangrude; S Heimfeld; I L Weissman
Journal:  Science       Date:  1988-07-01       Impact factor: 47.728

7.  Organization of the mouse RNA-specific adenosine deaminase Adar1 gene 5'-region and demonstration of STAT1-independent, STAT2-dependent transcriptional activation by interferon.

Authors:  Cyril X George; Sonali Das; Charles E Samuel
Journal:  Virology       Date:  2008-09-06       Impact factor: 3.616

Review 8.  Chemokines in hematopoiesis.

Authors:  Hal E Broxmeyer
Journal:  Curr Opin Hematol       Date:  2008-01       Impact factor: 3.284

9.  Expression of murine CD38 defines a population of long-term reconstituting hematopoietic stem cells.

Authors:  T D Randall; F E Lund; M C Howard; I L Weissman
Journal:  Blood       Date:  1996-05-15       Impact factor: 22.113

10.  Intermittent exposure of primitive quiescent chronic myeloid leukemia cells to granulocyte-colony stimulating factor in vitro promotes their elimination by imatinib mesylate.

Authors:  Heather G Jørgensen; Mhairi Copland; Elaine K Allan; Xiaoyan Jiang; Allen Eaves; Connie Eaves; Tessa L Holyoake
Journal:  Clin Cancer Res       Date:  2006-01-15       Impact factor: 12.531

View more
  184 in total

1.  The haematopoietic stem cell niche at a glance.

Authors:  Cristina Lo Celso; David T Scadden
Journal:  J Cell Sci       Date:  2011-11-01       Impact factor: 5.285

2.  Proteomic cornerstones of hematopoietic stem cell differentiation: distinct signatures of multipotent progenitors and myeloid committed cells.

Authors:  Daniel Klimmeck; Jenny Hansson; Simon Raffel; Sergey Y Vakhrushev; Andreas Trumpp; Jeroen Krijgsveld
Journal:  Mol Cell Proteomics       Date:  2012-03-27       Impact factor: 5.911

3.  Counting stem cells: methodological constraints.

Authors:  Leonid V Bystrykh; Evgenia Verovskaya; Erik Zwart; Mathilde Broekhuis; Gerald de Haan
Journal:  Nat Methods       Date:  2012-05-30       Impact factor: 28.547

4.  Regulating traffic in the hematopoietic stem cell niche.

Authors:  Marc H G P Raaijmakers
Journal:  Haematologica       Date:  2010-09       Impact factor: 9.941

Review 5.  Targeting leukemic stem cells by breaking their dormancy.

Authors:  Marieke Alida Gertruda Essers; Andreas Trumpp
Journal:  Mol Oncol       Date:  2010-06-09       Impact factor: 6.603

Review 6.  Therapy-related myeloid neoplasms: pathobiology and clinical characteristics.

Authors:  H Sill; W Olipitz; A Zebisch; E Schulz; A Wölfler
Journal:  Br J Pharmacol       Date:  2011-02       Impact factor: 8.739

7.  GATA-3 controls self-renewal in stressed HSCs.

Authors:  Toshimi Yoshida; Katia Georgopoulos
Journal:  Nat Immunol       Date:  2013-10       Impact factor: 25.606

8.  The control of hematopoietic stem cell maintenance, self-renewal, and differentiation by Mysm1-mediated epigenetic regulation.

Authors:  Tao Wang; Vijayalakshmi Nandakumar; Xiao-Xia Jiang; Lindsey Jones; An-Gang Yang; Xue F Huang; Si-Yi Chen
Journal:  Blood       Date:  2013-09-06       Impact factor: 22.113

Review 9.  Effects of type 1 diabetes-associated IFIH1 polymorphisms on MDA5 function and expression.

Authors:  Benjamin M Looney; Chang-Qing Xia; Patrick Concannon; David A Ostrov; Michael J Clare-Salzler
Journal:  Curr Diab Rep       Date:  2015-11       Impact factor: 4.810

10.  Cutting Edge: Direct Sensing of TLR7 Ligands and Type I IFN by the Common Myeloid Progenitor Promotes mTOR/PI3K-Dependent Emergency Myelopoiesis.

Authors:  Matthew B Buechler; Holly M Akilesh; Jessica A Hamerman
Journal:  J Immunol       Date:  2016-08-26       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.